Skip to main content
. 2016 Dec 18;5:23–34. doi: 10.1016/j.dadm.2016.12.005

Fig. 3.

Fig. 3

Association between SCD and Aβ status in HAS and patients with aMCI. Left panel: item-by-item analyses. Mann-Whitney tests were used to compare individuals with and without evidence of Aβ using Florbetapir-PET. The figure illustrates the effect size (r2 = Z2/n) of the comparison. Filled bars indicate that the group difference reached an uncorrected threshold of α = 0.05 (but none was significant when using Bonferroni procedure to correct 39 tests). Further description of item scores and statistical comparison is available in Supplementary Table 5 (for HAS) and Supplementary Table 6 (for patients with aMCI). Right panel: factor score analysis. After the (clinical group*factor*Aβ status) interaction was significant (F (1, 114) = 9.00, P = .003), a repeated model analysis of variance was conducted within each clinical group. P < .05, ∗∗P < .01. Scatterplot shows individual values, as well as 10th, 30th, 50th, 70th, and 90th percentiles within each group (black lines). Abbreviations: Aβ, β-amyloidosis; aMCI, amnestic mild cognitive impairment; HAS, healthy aged subjects; PET, positron emission tomography; SCD, subjective cognitive decline.